Page last updated: 2024-12-05
3,3',5-triiodothyropropionic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5804 |
| CHEMBL ID | 291053 |
| CHEBI ID | 135860 |
| SCHEMBL ID | 310201 |
| MeSH ID | M0058834 |
Synonyms (43)
| Synonym |
|---|
| thyropropic acid |
| hydrocinnamic acid, 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo- |
| 3,3',5-triiodothyropropionic acid |
| 51-26-3 |
| 3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]propanoic acid |
| smr000058682 |
| MLS000028680 |
| NCGC00018303-01 |
| bdbm18864 |
| triiodothyropropionic acid, 5 |
| 3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid |
| cid_5804 |
| CHEBI:135860 |
| CHEMBL291053 |
| benzenepropanoic acid, 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo- |
| NCGC00018303-02 |
| NCGC00018303-03 |
| thyropropic acid [inn] |
| acido tiropropico |
| ok7481s22o , |
| acidum thyropropicum |
| unii-ok7481s22o |
| acide thyropropique |
| acide thyropropique [inn-french] |
| acidum thyropropicum [inn-latin] |
| 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodobenzenepropanoic acid |
| acido tiropropico [inn-spanish] |
| 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodohydrocinnamic acid |
| FT-0675571 |
| thyropropic acid [mi] |
| 3,3',5-triiodo thyropropionic acid |
| SCHEMBL310201 |
| DTXSID20198998 |
| AKOS027380181 |
| SR-01000003172-2 |
| sr-01000003172 |
| 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid |
| triopron; triprop |
| Q27285698 |
| 3,3',5-triiodothyropropionic acid 100 microg/ml in acetonitrile |
| 1-benzyl-pyrrolidine-3-carboxylicacidamide |
| 3,3 inverted exclamation mark ,5-triiodo thyropropionic acid |
| 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoicacid |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (12)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 25.9185 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 50.1187 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 12.5893 | 0.0013 | 7.7625 | 44.6684 | AID914; AID915 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 10.0000 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 79.4328 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 89.1251 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 39.8107 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 0.3162 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Thyroid hormone receptor alpha | Homo sapiens (human) | IC50 (µMol) | 0.0000 | 0.0000 | 0.3549 | 4.5000 | AID1797782; AID213163; AID311016 |
| Thyroid hormone receptor beta | Homo sapiens (human) | IC50 (µMol) | 0.0000 | 0.0000 | 0.5018 | 5.1286 | AID1797784; AID213175; AID299948; AID311017 |
| Proliferating cell nuclear antigen | Homo sapiens (human) | IC50 (µMol) | 17.0000 | 3.6000 | 4.9500 | 6.3000 | AID739861 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| electroneutral potassium-chloride cotransporter KCC2 | Homo sapiens (human) | EC50 (µMol) | 4.2500 | 0.4810 | 1.5303 | 2.3100 | AID1736 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (54)
Molecular Functions (28)
Ceullar Components (17)
Bioassays (18)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID213175 | Concentration required to inhibit 50% of I-T3 binding to hTR1 (Thyroid hormone receptor beta) was determined | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9 | Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. |
| AID75733 | Effect on rat hepatic glycerophosphate dehydrogenase alpha (GPD) activity 3 days after injection of 10e-6 mol/kg. | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity. |
| AID213163 | Concentration required to inhibit 50% of I-T3 binding to hTR1 (Thyroid hormone receptor alpha) was determined | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9 | Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. |
| AID739861 | Inhibition of human recombinant PCNA interaction with PIP box protein N-5-carboxyfluorescein-SAVLQKKITDYFHPKK after 30 mins by fluorescence polarization assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7 | Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis. |
| AID170336 | Effect on the plasma cholesterol levels after subcutaneous administration of 8 nmol/kg in Dawley rats. | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity. |
| AID104520 | Effect on rat hepatic Malic enzyme activity 3 days after injection of 10e-6 mol/kg. | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity. |
| AID170334 | Effect on the plasma cholesterol levels after subcutaneous administration of 16 nmol/kg in Dawley rats. p < 0.01 | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity. |
| AID299948 | Inhibition of human thyroid hormone receptor beta 1 | 2007 | Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15 | QSAR study of selective ligands for the thyroid hormone receptor beta. |
| AID104519 | Effect on rat hepatic Malic enzyme activity 3 days after injection of 10e-5 mol/kg. | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity. |
| AID231783 | Ratio of concentration required to inhibit 50% of I-T3 binding to hTR-alpha1 to that of concentration required to inhibit 50% of I-T3 binding to hTR-beta1 was determined | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9 | Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. |
| AID75734 | Effect on rat hepatic glycerophosphate dehydrogenase alpha (GPD) activity relative to L-T3. | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity. |
| AID311017 | Inhibition of thyroid hormone receptor beta | 2007 | Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13 | 2D QSAR studies on thyroid hormone receptor ligands. |
| AID311016 | Inhibition of thyroid hormone receptor alpha | 2007 | Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13 | 2D QSAR studies on thyroid hormone receptor ligands. |
| AID104517 | Effect on rat hepatic Malic enzyme activity relative to L-T3. | 1992 | Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3 | alpha-Methylated analogues of triiodothyroalkanoic acids: synthesis and biological activity. |
| AID1797782 | TRalpha-Binding Assay. from Article 10.1021/jm021080f: \\Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.\\ | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9 | Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. |
| AID1797784 | TRbeta-Binding Assay from Article 10.1021/jm021080f: \\Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.\\ | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9 | Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.64) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||